PPAR has been one of the most active therapeutic targets for NASH during last years, and their subtypes including PPARα, PPARδ and PPARɣ has been reported to play homeostatic role in the liver [46]. The gene discussed is PPARD; the disease is metabolic dysfunction-associated steatohepatitis.